5-Amino-1MQ 10mg we yu de yuz

▎ 5-Amino-1MQ Struktrɔ

▎ 5-Amino-1MQ Risach

Wetin na di risach bakgrɔn fɔ 5-Amino-1MQ?

Wit di kɔntinyu we di glob ɔl insidɛns rɛt fɔ mɛtabolik sik dɛn lɛk fɔ fat ɛn dayabitis, fɔ no di target ɛn drɔgs we go ebul fɔ rigul di ɛnaji mɛtabolism fayn fayn wan ɛn impruv mɛtabolik dizayd dɔn bi wan impɔtant risach fɔs. Nikotinamid N-methyltransferase (NNMT), we na wan ki mεtabolik εnzym, de ple imכtant rol fכ enεji homכstasis. i ova εksprεshכn de lid to εshyu dεm lεk fεt akyumyuleshכn εn insulin rεsistεns, we de mek NNMT rεguleshכn bi pכtεnshal tεrapi tכgεt fכ rilayt sik dεm.

Agens dis bakdrop, 5-Amino-1MQ dכn kכmכt as spεsifi k NNMT inhibito. bay we i de sכpres NNMT aktiviti, i de ridyus abnכmal nikotinamid mεtyleshכn, rεstכr intasεlulyar NAD+ lεvεl dεm εn nכmal riletid signal path dεm, we de impruv lipid mεtabolism εn εnhans insulin sεnsitiviti. 5-Amino-1-methylquinolinium dכn kכmכt as wan ki risεch tכgεt fכ εksplכr nכvel tεrapi stratεji dεm εgεst mεtabolik dizכrd, we de spur fכndamεntכl stכdi dεm pan in mεkanism dεm.

Us ifekt dεm 5-Amino-1-methylquinolinium de gi pan adiposyt mεtabolism?

Efεkt dεm pan Adipogenesis

inhibishכn fכ Adipojenεsis: adipojεnεsis de tכk bכt di prכsεs usay di prεadiposyt dεm de difrεnt to machכ adiposyt dεm εn de akכmyule lipid dεm we di adiposyt dεm de divεlכp. rεsכch sho se mεtylquinolinium sכfכld dεm we de bεr praymar amin sכbstityuεnt dεm de sho hכy pεrmiabiliti fכ כl tu di pasiv εn aktv transmεmbran transpכt, we dεn analכg dεm de sho hεli sεlektiv inhibitory aktiviti εgεst nikotinamid N-methyltransferase (NNMT) ^[1] . NNMT inhibito dεm de sכpres adipojenεsis insay adiposyt dεm, we de mek di haypothεsis se 5-Amino-1-methylquinolinium, if i gεt di sem kayn NNMT inhibitory aktiviti, i go rili rεdכks adipojenεsis bay we i de inhεbit NNMT. fכ egzampl, insay kכlt adiposyt εkspεriεns, NNMT inhibito dεm de dכn di intasεlulyar 1-methylnicotinamide (1-MNA) lεvεl dεm, inkrεs intasεlulyar nikotinamid adenine dinucleotide (NAD−) εn S-(5'-adenosyl) -L-methionine (SAM), εn inhεbit adipojenεsis insay fεt sεl dεm ^{[1] .}.

infכmeshכn fכ adipojεnεsis-rεlatεd jin εksprεshכn: Adipojεnεsis de rεgεl bay wan siriכs transkripshכn fכktכ dεm εn jin dεm, lεk pεrכksisom proliferator-aktivεt rεsεptכr-gamma (PPAR-γ) εn CCAAT/εnhans-bכnd protin (C/EBP). methylquinoline dεrivεt dεm inevitably infכlכw lipojεnεsis bay we dεn de afekt di εksprεshכn fכ dεn ki jin dεm ya.

Figure 1 Sεlektiv εn mεmbran-pεrmiabl sכm mכlikul inhibito dεm fכ nikotinamid N-mεtyltransfεrayz rivεs hεy fεt dεyt-indyuz כbisiti in mays.

Sos: SaynsDayrɛkt ^{[1] .}

Efεkt dεm pan Lipid Mεtabolism

rεgulεshכn fכ di protin dεm we de involv insay lipid sεntez εn dεgradashכn: di lipid mεtabolism de kכmכp prכsεs dεm lεk lipid sεntez, stכrej, εn dεgradashכn. insay stכdi dεm fכ mεtabolik-asכsiet fεt liva sik (MAFLD), Donglingcao de mכdulet di aktvכti fכ pεrכksisom proliferεt-aktivεt rεsεptכr -α (PPAR-α), stεrכl rεgεdyushכn εlimεnt-bכnd protin-1c (SREBP-1c), fεt asid sεntez (FAS), εn asetil-CoA kכbכksilayz (ACC). 5-Amino-1-methylquinolinium kin infכlכw di lipid mεtabolism insay adiposyt dεm tru wan sεm kayn mεkanism, dat na bay we i de rεgεl di εksprεshכn fכ dεn ki protin dεm we de involv insay lipid sεntez εn dεgradashכn. fכ egzampl, if 5-Amino-1-methylquinolinium kin upregulate PPAR-α εksprεshכn, i kin promuot fεt asid כksidεshכn εn ridyus lipid akyumyuleshכn insay adiposyt dεm. di kכnvεshכn, if i afekt di εksprεshכn fכ SREBP-1c, FAS, εn כda wan dεm, i kin infכlכw fεt asid sεntesis prכsεs dεm.

כltεr di intasεlulyar mεtabolit lεvεl dεm fכ infכlכ di lipid mεtabolism: di intasεlulyar mεtabolit lεvεl dεm de ple wan imכtant rεgεdyushכn rol insay lipid mεtabolism. as wi bin dכn tכk, NNMT inhibito dεm kin mכdify intasεlulyar lεvεl dεm fכ mεtabolit dεm lεk 1-MNA, NAD+, εn SAM, we de afekt adiposyt mεtabolism ^[1] . if 5-Amino-1-methylquinolinium prodyuz di sem kayn ifekt pan dεn mεtabolit lεvεl dεm, i go indayktli rεgεl di lipid mεtabolism. as imכtant intasεlulyar kכεnzym we involv insay mכltipכl mεtabolik path dεm, כltεrayshכn dεm na di NAD+ lεvεl dεm kin infכlכw lipid mεtabolism-rεlatεd prכsεs dεm lεk fεt asid כksidεshכn εn di trikarbכksilik asid saykl.

Efεkt dεm pan εnεji mεtabolism

ifekt dεm pan di maytochכndrial aktvכti: di εnεji mεtabolism insay di adiposyt dεm de kכlכs fכ di maytochכndrial fכnshכn. stכdi dεm sho se כnda in vitro simulεt statik strεch kכndishכn dεm, maytochכndrial aktiviti insay adiposyt dεm de inkrεs, we de protεkt lipojεnεsis εn aksεlεrayt sεlyul mεtabolism ^[2] . mεtylquinolinium kכmpawnd dεm kin altεr di maytochכndrial aktiviti bay we dεn de infכlכw di maytochכndrial-rεlatεd mεtabolik path dεm כ protin εksprεshכn. if 5-Amino-1-methylquinolinium inhεbit sכm ki maytochכndrial protin dεm כ mεtabolik prכsεs dεm, i kin ridyus di maytochכndrial aktiviti εn dכn dכn εnεji εkspεndishכn insay adiposyt dεm. di kכnvεshכn, i kin mek di εnεji mεtabolism. fכ egzampl, bay we i de afekt di aktiviti fכ di maytochכndrial rεspiretכri chen kכmpleks dεm, i kin rεgεl ATP prodakshכn, we de infכlכ di enεji stet εn mεtabolik dεyshכn fכ di adiposyt dεm.

rεgεl di adiposyt εnεji bεlε: di adiposyt dεm nכ de nכmכ de stכr εnεji bכt dεn de tek pat pan εnεji bεlε rεgulεshכn. di ifekt dεm we 5-Amino-1-methylquinolinium gεt pan adiposyt mεtabolism kin fכs fכ sho insay enεji bεlε rεguleshכn. if i de inhibit lipojenεsis εn protεkt lipolysis, i kin ridyus di enεji stכrej εn inkrεs εnεji rilis insay adiposyt dεm. di kכnvεshכn, if i de protεkt lipojεnεsis εn inhεbit lipolysis, i kin mek di εnεji we pasmak insay di adiposyt dεm, we de ambɔg di εnεji bεlε—we na imכtant tin fכ divεlכpmεnt fכ fat εn di mεtabolik dizכrd dεm we de kכmכt wit am.

Efεkt dεm pan Adipocyte εndokrin Fכnshכn

influεns adipokine sekreshכn: as εndokrin כgan dεm, adiposyt dεm de sekret mכltipכl adipokine dεm lεk lεptin εn adiponectin, we de ple imכtant rεgεdyushכn rol dεm insay sistεmik mεtabolism ^[3] . sכm dכg כ sכbstans dεm kin infכlכ di adiposyt sekreshכn fכ dεn adipokines dεm ya. pan tap we nכ dayrekt pruf de fכ 5-Amino-1-methylquinolinium in ifekt pan adipokine sekreshכn, in כvala impak pan adiposyt mεtabolism de sho se pכtεnshal indaykt rεguleshכn fכ adipokine sekreshכn. if 5-Amino-1-methylquinolinium altεr adiposyt enεji stetכs כ lipid mεtabolism, i kin fכdbכk-rεgulεt lεptin sekreshכn. as signal mכlikul we de sho di fεt stכr dεm, chenj dεm na di lεptin sekreshכn de infכlכw di apetit εn εnεji mεtabolism.

Influεns Inflammatory Cytokine Sekreshכn: di inflammatory stet fכ di adipos tisu de kכlכs fכ di adiposyt mεtabolism. di adiposyt dεm kin sekret difrεn inflammatory saytokεn dεm, lεk intalyukin-1β (IL-1β), intalyukin-6 (IL-6), εn tכmכro nεkrכsis fכktכ-α (TNF-α) (Michalczyk K). insay di stet dεm we fat pasmak, di inkrεs pan di adipos tisu inflameshn de mek di sekreshכn fכ dεn inflammatory fכktכ dεm ya de hεy, afta dat i de afekt di sistεmik mεtabolism εn insulin sεnsitiviti. 5-Amino-1-methylquinolinium, if i ebul fכ rεgεl di adiposyt mεtabolism, i kin altεr di saytokεn sekreshכn, we de infכlכ di inflammatory maykro envayroment fכ di adipose tisu εn afekt di mεtabolik komplikashכn dεm we rilayt fכ fat. di potenshal fכ inhεbit saytokεn sekreshכn kin εp fכ mitigate insulin rεsistεns εn impruv mεtabolik stetכs.

Bɔt di pɔsin we rayt di buk

Di tin dɛn we wi dɔn tɔk bɔt ɔp, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.

Sayɛns Jɔnal Author

Harshini Neelakantan na famasitik sayɛnsman ɛn risach lida wit bɔku ɛkspiriɛns pan prɛklinik drɔg divɛlɔpmɛnt fɔ mɛtabolik, nyurolɔjik, ɛn mɔskul skel dizayd. Naw, i de wok as Ɛgzibit Dayrɛktɔ fɔ Risach & Divɛlɔpmɛnt na Ridgeline Therapeutics, we de pe atɛnshɔn pan di transleshɔn fɔ smɔl-mɔlikul tɛrapi frɔm hit-to-lid validɛshɔn to klinik aplikeshɔn. in εkspεriεns span in vivo fכmakכlכji, sik mכdelin, εn drog mεtabolism, εn i bin de wok bifo na di Yunivasiti כf Tεksas Mεdikal Branch.Harshini Neelakantan dεn list am na di rεfrεns fכ saytεshכn [1].

▎ Saytayshɔn dɛn we gɛt fɔ du wit dis

[1] Neelakantan H, Vans V, Wetzel M. D., ɛn ɔda pipul dɛn. sεlektiv εn mεmbran-pεrmiabl sכm mכlikul inhibito dεm fכ nikotinamid N-mεtyltransfεrayz rivεs hεy fεt dεyt-indyuz כbisiti in mays. Bayokɛmikɛl Famakɔlɔji 2018; 147: 141-152.DOI: 10.1016/j.bcp.2017.11.007.

[2] Mor-Yossef ML, Kislev N, Lustig M, Pomeraniec L, Benayahu D. Bayomεkanikal stimulashכn ifekt dεm pan di mεtabolism fכ adiposyt. J ɔ rnal ɔ f Sεlyul Fisiɔlɔji 2020; 235(11): 8702-8713.DOI: 10.1002/jcp.29714.

[3] Michalczyk K, Niklas N, Rychlicka M, Cymbaluk-Płoska A. Di Influεns כf Bayolojikal Aktiv Sכbstans dεm we di Adipכz Tisu Sekret pan εndometrial Kεnsar. Diagnostik 2021 we dɛn kɔl; 11(3).DOI: 10.3390/diagnostiks11030494. Di wan dɛn we de stɔdi bɔt di sik.

ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.  

Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.